Skip to main content

Table 5 Extent of mono- and combination drug therapy use in the female LUTS (including OAB) sub-cohort

From: The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

Monotherapy N % of monotherapy patients % of all patients in female OAB sub-cohort % of all female patients
Any OAB drug monotherapy 26,338 100.0 90.5 85.6
Any antimuscarinic monotherapy 24,263 92.1 83.4 78.8
Solifenacin 10,083 38.3 34.7 32.8
Oxybutynin 7852 29.8 27.0 25.5
Tolterodine 4020 15.3 13.8 13.1
Mirabegron 2075 7.9 7.1 6.7
Fesoterodine 1173 4.5 4.0 3.8
Trospium 754 2.9 2.6 2.4
Darifenacin 209 0.8 0.7 0.7
Flavoxate 96 0.4 0.3 0.3
Propiverine 76 0.3 0.3 0.2
Combination drug therapy N % of combination drug therapy patients % of all patients in female OAB sub-cohort % of all female patients
All combination drug therapy 2756 100.0 9.5 9.0
Any ≥ 2 OAB drugs 2621 95.1 9.0 8.5
Mirabegron + any antimuscarinic 788 28.6 2.7 2.6
Any ≥ 2 antimuscarinics (± mirabegron) 1847 67.0 6.3 6.0
Duloxetine + any OAB drug 144 5.2 0.5 0.5
Solifenacin + tolterodine 507 18.4 1.7 1.6
Oxybutynin + solifenacin 458 16.6 1.6 1.5
Mirabegron + solifenacin 417 15.1 1.4 1.4
Fesoterodine + solifenacin 174 6.3 0.6 0.6
Oxybutynin + tolterodine 174 6.3 0.6 0.6
Other combinations 1026 37.2 3.5 3.3
Drug class N % of all patient in OAB sub-cohort % of all female patients
Any OAB drug 29,094 100 94.5
Any antimuscarinic 27,010 92.8 87.7
Total mirabegron 2972 10.2 9.7
  1. LUTS: lower urinary tract symptoms; OAB: overactive bladder